BIOMAT Database Logo BIOMAT Database Logo

Adjuvant tamoxifen in postmenopausal stage II breast cancer five years on. 1990

J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski

UI MeSH Term Description Entries
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.
May 1997, Journal of the National Cancer Institute,
J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski
Adjuvant chemotherapy combined with tamoxifen in postmenopausal patients with stage II breast cancer.
November 1986, Lancet (London, England),
J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
November 1996, Journal of the National Cancer Institute,
J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski
ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer.
December 2000, Annals of oncology : official journal of the European Society for Medical Oncology,
J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski
One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
September 2013, European journal of cancer (Oxford, England : 1990),
J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski
Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
December 2003, Clinical breast cancer,
J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski
Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer.
January 1993, European journal of cancer (Oxford, England : 1990),
J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
July 2006, The American journal of managed care,
J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
November 2003, The New England journal of medicine,
J Mikl, and P Aiginger, and K Czerwenka, and E Kubista, and H Salzer, and P Sevelda, and J Spona, and A Staffen, and C C Zielinski
Letrozole in postmenopausal women after five years on tamoxifen.
January 2004, Current oncology reports,
Copied contents to your clipboard!